Antibiotic prophylaxis and complications following prostate biopsies:A systematic review by Klemann, Nina et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Antibiotic prophylaxis and complications following prostate biopsies
Klemann, Nina; Helgstrand, John Thomas; Brasso, Klaus; Vainer, Ben; Iversen, Peter; Røder,
Martin Andreas
Published in:
Danish Medical Journal
Publication date:
2017
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY-NC
Citation for published version (APA):
Klemann, N., Helgstrand, J. T., Brasso, K., Vainer, B., Iversen, P., & Røder, M. A. (2017). Antibiotic prophylaxis
and complications following prostate biopsies: A systematic review. Danish Medical Journal, 64(1), [A5323].
Download date: 03. Feb. 2020
Dan Med J 64/1  January 2017 da n i s h m E d i c a l J O U R n a l   1
abstRact
IntroductIon: Transrectal ultrasound-guided biopsies 
(TRUS-gb) are associated with both mild and serious compli-
cations. Prophylactic antibiotics reduce the risk of septic-
aemia and mortality; however, no international consensus 
exists on the timing and duration of antibiotics, including 
the optimal drug strategy. We reviewed the current evi-
dence supporting use of prophylactic antibiotics and the 
risk of complications following prostate biopsies. 
Methods: This review was drafted in accordance with the 
Prisma Guidelines. The PubMed, Embase and Cochrane  
databases were searched. 
results: A total of 19 eligible trials were identified. One  
trial demonstrated a significant reduction in the risk of in-
fection after biopsy and reported that oral ciprofloxacin as 
either a single-dose or a three-day regimen was superior to 
oral chloramphenicol and norfloxacin. Of three studies in-
vestigating the timing of the first dose of antibiotic, one 
study found that administration 24 h before biopsy versus 
administration immediately before reduced the relative risk 
of post-biopsy infection by 55%. Seven studies compared 
different durations of antibiotic prophylaxis. None showed 
any benefit from continuing prophylaxis beyond a single 
dose or a one-day regimen. 
conclusIon: Evidence supporting a specific antibiotic regi-
men for TRUS-gb prophylaxis is scarce. Widespread use of 
fluoroquinolone prophylaxis may be associated with an in-
crease in resistant Escherichia coli strains, posing a poten-
tially major health issue in the future.  
During the past three decades, the epidemiology of 
pros tate cancer (PCa) has changed dramatically and, ex-
cluding non-melanoma skin cancer, PCa is now the most 
common male cancer diagnosis in most Western coun-
tries [1]. The 4-8% annual increase in PCa incidence ob-
served in high-resource countries is mainly attributed to 
a growing awareness of PCa and the widespread use of 
prostate-specific antigen (PSA) testing. Prostate biopsy 
remains the mainstay in the diagnosis of PCa, and sys-
tematic transrectal ultrasound-guided biopsies (TRUS-
gb) of the prostate is the gold standard technique. The 
procedure may be associated with mild or serious ad-
verse events, most importantly infectious complications 
[2-4], but no international consensus exists on the use of 
antibiotics prior to and after TRUS-gb. In Denmark (DK), 
approximately 10,000 TRUS-guided biopsy sets are per-
formed annually, but the frequency of complications 
and infections remains unknown. We systematically re-
viewed the current evidence of post-biopsy complica-
tions and the use of prophylactic antibiotics and dis-
cussed the use of antibiotic regimens in DK.  
mEthOds
This review was drafted in accordance with the Prisma 
Guidelines [5]. Three different searches in the PubMed, 
Embase and Cochrane databases were performed using 
the search strings: 
1: biopsy AND prostate AND (prophylaxis OR prophylac-
tic) AND antibiotic 
2: biopsy AND prostate AND infection AND bacteria
3: biopsy AND prostate AND resistance.
In PubMed, the limits set were “adult:  19+ years”, and 
“humans”. In Embase, limits were “humans”, “adult 18 
to 64” and “Aged 65+ years” and publication year 2005-
2015. 
In the PubMed and Cochrane databases, publica-
tion year was limited to the period from 2005 to the pre-
sent was used. Only randomised controlled trials (RCT) 
reported in English and full-text articles were included, 
but prospective trials originating from Europe were 
screened in order to further examine regimens and rec-
ommendations of countries in relative proximity to DK. 
Finally, we identified the literature originating from DK.
Based on titles, all relevant abstracts were read, 
and the selected articles were evaluated for eligibility.  
A flow chart is presented in Figure 1. All retrospective 
studies, reviews and case reports were excluded, unless 
originating from DK, as were papers deemed irrelevant 
because of their subject, e.g. papers on other cancer 
forms than PCa.
All Danish urology departments performing TRUS-
gb were identified and contacted to obtain information 
about biopsy technique and use of prophylactic anti-
biotic strategy, including antibiotic dose and duration 
used. For information about development of resistant 
bacterial strains in DK, we reviewed the DANMAP, a 
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Danish programme for surveillance of antibiotic con-
sumption and bacterial resistance in humans.
REsUlts
We identified 19 eligible trials: ten randomised trials, 
seven prospective trials and two retrospective trials. 
Four of the randomised trials originated from Europe, 
two from Asia, one from North America, two from  
South America and one from Canada. Two retrospective  
studies from DK were identified. A total of 295 papers 
were excluded; 18 were not available in English, 275 
were irrelevant (e.g. case reports) and two papers were 
not available in full text. The study characteristics are 
listed in table 1. 
Post-biopsy complications were described in all of 
the included trials. Non-infectious complications, regard-
less of study type, included haematuria (14.3-62.3%), 
haemospermia (17.8-59.1%) and rectal bleeding (4.8-
21%) [6-13]. The post-biopsy infectious complications 
ranged from post-bioptic positive urine cultures (0.9-
18.1%), urinary tract infection (UTI) (0.8-9.3%), prostatitis 
(0.67-0.7%), epididymitis (0.4%) and dysuria (0.4-13.3%), 
to more severe complications such as fever (0.3-8.6%), 
need for hospitalisation (0.4-3.1%), sepsis (0.17-5.7%), 
septic shock (0.2-0.45%) and death (0.2%) [6, 7, 9-22].
type of antibiotic
Five trials comparing different prophylactic antibiotic 
regimens were identified. In these regimens, the admin-
istration of antibiotics was initiated between 30 minutes 
and 24 hours prior to biopsy.
All of the five trials were RCTs. The first study ran-
domised patients to either tosufloxacin or levofloxacin 
orally, both in a two-day administration [9]. The second 
study randomised patients into three groups receiving 
either a single dose of ceftriaxone i.m., a single dose of 
ciprofloxacin (CFLX) orally or a three-day course of CFLX 
orally [11]. The third study randomised patients into 
four arms receiving CFLX or levofloxacin as either single 
doses or as a three-day regimen [8]. The fourth study 
randomised patients to receive CFLX with or without the 
addition of a periprostatic injection of cephalosporin 
[12]. None of the studies demonstrated any differences 
in the infectious or non-infectious complication rates fol-
lowing TRUS-gb. However, the fifth study showed that 
quinolones are superior to chloramphenicol in reducing 
infectious complications [22]. The trial randomised pa-
tients in a four-armed study comparing oral CFLX as ei-
ther a single-dose or a three-day regimen to chloram-
phenicol and norfloxacin orally, both as three-day 
regimens. The study found a significant reduction in the 
risk of post-biopsy infections favouring CFLX both as sin-
gle-dose and as three-day regimen compared with chlor-
amphenicol (p = 0.0003) and norfloxacin (p = 0.03).
Route and timing of administration of prophylaxis 
No studies have compared intravenous to oral adminis-
tration of prophylactic antibiotics prior to TRUS-gb. We 
identified three studies investigating the importance of 
the timing of the initial dose of antibiotic. A prospective 
trial evaluated two different antibiotic strategies during 
two consecutive years. In the first year, the first dose of 
antibiotic was administered immediately before the bi-
opsy procedure, and in the second year the antibiotic 
was administered 24 hours before biopsy. The study 
concluded that administration 24 hours before biopsies 
resulted in a relative risk reduction for post-biopsy infec-
tion of 55% compared with antibiotics just prior to the 
procedure [15]. 
FigURE 1
Flow chart presenting the literature selection process.
Records identiﬁed through 
database searching (n = 986)
Records after duplicate were removed (n = 930)
Records screened (n = 930)
Additional records identiﬁed
through other sources (n = 5)
Records excluded (N = 295)
Language (n = 18)
Relevance (n = 275)
Full-text not available (n = 2)
Full-text articles assessed for eligibility (n = 635)
Studies included in qualitative synthesis (n = 19)
Full-text articles excluded 
(N = 616)
Orgin (n = 119)
Study design (n = 180)
Case report (n = 56)
Relevance (n = 261)
KEY POints
Transrectal ultrasound-guided biopsy (TRUS-gb) of the prostate is con-
sidered the mainstay in the diagnosis of men at risk of harbouring pros-
tate cancer.
Both the annual number of biopsy sets and the number of biopsy cores 
per biopsy set have increased over time in Denmark.
TRUS-gb is associated with both mild and serious complications, ranging 
from dysuria to sepsis and death.
Prophylactic antibiotics reduce the risk of infectious complications after 
TRUS-gb, but no national or international consensus on the use of anti-
biotic prophylaxis exists.
Frequent use of antibiotics in the general population, development of  
resistant bacteria and the fact that many patients undergo re-biopsies 
complicate the introduction of a uniform, prophylactic antibiotic strategy.
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Another study randomised patients to oral levoflox-
acin 500 mg given either 30-60 minutes before TRUS-gb 
or immediately after the bioptic procedure, but found 
no differences in infectious complications [7]. Finally,  
a prospective trial compared a single dose of oral CFLX 
750 mg given either two hours before or in conjunction 
with the biopsy procedure, but failed to demonstrate a 
significant impact on the risk of infectious complications 
[13]. 
duration of prophylaxis  
Several studies have compared the duration of antibiot-
ics during TRUS-gb administered either as a single dose, 
a one-day regimen or a three-day regimen. One study 
[14] compared a single dose of 400 mg norfloxacin with 
a regimen of 400 mg immediately before the biopsies 
followed by three days of 400 mg norfloxacin twice  
daily. No statistically significant difference in the risk of 
complications (p = 0.07) was demonstrated. An add-
itional six studies compared different durations of anti-
biotic prophylaxis for TRUS-gb procedures, but none 
were able to show a benefit of continuing prophylaxis 
for more than a single dose [6, 10, 11, 16, 22] or a three-
day [8] regimen. 
isolated bacteria
Bacteria isolated from blood or urine were Escherichia 
coli in 30-100% of the affected cases, Klebsiella spp. in 
4-15% and Pseudomonas spp. in up to 14%, but also  
Enterococcus, Enterobacter, Staphylococcus aureus,  
tablE 1
Study characteristics.
Reference design Result
Type of antibiotic
Tobias-Machado et al [22] Ciprofloxacin for 1 day  
Ciprofloxacin for 3 days 
Chloramphenicol for 3 days 
Norfloxacin for 3 days
Ciprofloxacin (1 and 3 days) significantly reduces  
post-procedural infection rates
Yamamoto et al [9] Tosufloxacin for 2 days 
Levofloxacin for 2 days
No difference in rates of infectious complications
Cam et al [11] Ceftriaxon i.m. single dose 
Ciprofloxacin single dose 
Ciprofloxacin for 3 days
No difference in rates of infectious complications
Sabbagh et al [8] Ciprofloxacin single dose or for 3 days  
Levofloxacin single dose or for 3 days
No difference in rates of infectious complications
Pace et al [12] Ciprofloxacin ± cephalosporin injection No difference in rates of infectious complications
Timing of administration of prophylaxis
Manecksha et al [15] Ofloxacin 400 mg immediately before biopsy + 200 mg BID for 3 days 
Ofloxacin 200 mg BID for 3 days, 1st dose 24 h prior to biopsy
Administration 24 h before biopsy yields a 55% relative risk  
reduction for post-biopsy infection
Argyropoulos et al [7] Levofloxacin 500 mg 30 min prior to biopsy 
Levofloxacin 500 mg immediately after prostate biopsy
No difference in rates of infectious complications
Lindstedt et al [13] Ciprofloxacin 750 mg 2 h before biopsy 
Ciprofloxacin 750 mg in direct conjunction with biopsy
No difference in rates of infectious complications
Duration of prophylaxis
Petteffi et al [14] Norfloxaxin 400 mg single dose 
Norfloxacin 400 mg for 3 days
No difference in rates of minor post-bioptic  
complications
Aron et al [6] Placebo for 3 days 
Ciprofloxacin 500 mg + tinidazole 600 mg single dose 
Ciprofloxacin 500 mg + tinidazole 600 mg single dose,  
BID for 3 days
No difference in rates of infectious post-bioptic complications  
between groups 2 and 3 
Significantly higher incidence of infection in group 1: placebo
Briffaux et al [10] Ciprofloxacin 1 g single dose 
Ciprofloxacin 500 mg BID for 3 days
No difference in rates of post-bioptic complications
Cam et al [11] Ceftriaxone 1 g i.m. single dose 
Ciprofloxacin for 3 days 
Ciprofloxacin 500 mg single dose
No difference in rates of post-bioptic complications
Schaeffer et al [16] Ciprofloxacin 1 g single dose 
Ciprofloxacin 1 g for 3 days
No difference in rates of post-bioptic complications
Tobias-Machado et al [22] Ciprofloxacin for 1 day 
Ciprofloxacin for 3 days 
Chloramphenicol for 3 days 
Norfloxacin for 3 days
No difference between a single-dose and a 3-day regimen  
of ciprofloxacin
Sabbagh et al [8] Ciprofloxacin single dose or for 3 days  
Levofloxacin single dose or for 3 days
No difference in rates of post-bioptic complications
BID = 2 × daily; i.m. = intramuscularly.
 4  da n i s h m E d i c a l J O U R n a l Dan Med J 64/1  January 2017
Proteus mirabilis and Streptococcus were found. One  
trial reported infections to be caused by Gram-negative 
species (e.g. E.coli, Enterobacter and Klebsiella) in 81% 
of cases, but did not name the isolated bacteria strains 
[5, 8-21].
Resistance/sensitivity of bacteria 
Several the bacterial strains isolated from the blood 
and/or urine of patients admitted with complications 
following TRUS-gb were found to be resistant to the 
most commonly used antibiotics, i.e. quinolones, ceph-
tablE 2
Prophylactic antibiotics 
used for transrectal ultra-
sound-guided biopsy in 
Denmark.
Capital Region of Denmark 
Rigshospitalet: 10 cores 
Amoxicillin/clavulanic acid 500/125 mg orally and mecillinam 400 mg orally the evening before and again 2 h prior to the scheduled appointment 
The dose is to be repeated 3 × a day for a total of 2 days after the biopsy procedure
Herlev: 10-12 cores 
Amoxicillin/clavulanic acid 500/125 mg orally and mecillinam 400 mg orally the evening before and again 2 h prior to the scheduled appointment 
The dose is to be repeated 3 × a day for a total of 2 days after the biopsy procedure
Frederiksberg: 12 cores 
Amoxicillin/clavulanic acid 500/125 mg orally and mecillinam 400 mg orally the evening before and again 2 h prior to the scheduled appointment 
The dose is to be repeated 3 × a day for a total of 2 days after the biopsy procedure
Region Zealand 
Roskilde: 10-12 cores 
Ciprofloxacin 500 mg orally and metronidazol 1 g orally taken at the time of biopsy, 6 h after and again the following morning
Næstved: 12 cores 
Ciprofloxacin 500 mg orally and metronidazol 500 mg orally at the time of biopsy repeated on the evening of the procedure and again the following 
morning
Rønne: 10 cores 
Ciprofloxacin 1 g 1 h before the procedure, repeated 6 h after the procedure 
In case of diabetes or surgically implanted foreign bodies, a further 500 mg orally BID for 3 days is added
Region of Southern Denmark  
Fredericia: 12 cores 
Ciprofloxacin 500 mg orally and metronidazol 500 mg orally at the time of biopsy and repeated 6-8 h after the procedure
Odense: 12 cores 
Ciprofloxacin 500 mg orally at the time of biopsy repeated on the evening of the procedure
Esbjerg: 12 cores 
Ciprofloxacin 500 mg orally before the procedure, repeated 8-10 h later 
In case of repeat biopsies or if seed implantation is planned within 6 mo.s, the prophylaxis is expanded to ciprofloxacin 1 g × 2 and amoxicillin/clavu-
lanic acid 500/125 mg orally BID  for a total of 3 days
Sønderborg: 12 cores 
Ciprofloxacin 500 mg orally 
The 1st dose shortly before the procedure and repeated the same evening
Svendborg: 12 cores 
Ciprofloxacin 500 mg orally at the time of biopsy, repeated on the evening of the procedure and in the morning and evening on the following day
Central Denmark Region 
Aarhus University Hospital: 10 cores 
Ciprofloxacin 1 g orally 1 h before the procedure
Randers: 10 cores 
Ciprofloxacin 1 g as a single dose 1 h before the procedure
Horsens: 10 cores 
Ciprofloxacin 1 g orally before the procedure 
If the patient has diabetes the prophylaxis is extended to ciprofloxacin 500 mg orally BID for 3 days
Viborg: 12 cores 
Ciprofloxacin 500 mg orally 
The 1st dose shortly before the procedure and repeated the same evening
Holstebro: 12 cores 
Ciprofloxacin 500 mg p.o. 
The 1st dose shortly before the procedure and repeated the same evening
North Denmark Region 
Aalborg: 12 cores 
Ciprofloxacin 500 mg before and 6 h after the biopsy procedure
Frederikshavn: 12 cores 
Ciprofloxacin 1 g as a single dose before the procedure
Thisted: 12 cores 
Ciprofloxacin 500 mg before and 6 h after the biopsy procedure
BID = 2 × daily; p.o. = orally.
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alosporins, aminopenicillins (i.e. ampicillin, amoxicillin) 
and aminoglycosides [9, 10, 12, 15, 17-21]. Bacterial sen-
sitivity towards the most commonly used antibiotics was 
demonstrated in several studies, including cephalospor-
ins, carbapenem/imipenem/meropenem, and amikacin 
[9, 12, 15, 17, 20, 21]. In one study, rectal swabs were 
performed immediately prior to the prostate biopsy. 
Among 236 rectal cultures obtained, 58 contained bac-
teria resistant to CFLX; of these, 52 were E. coli [21].  
Another trial also obtained rectal swabs immediately  
before the biopsy procedure and found that 19% of pa-
tients were colonised with extended spectrum beta- 
lactamase (ESBL)-producing E. coli (ESBL-PE) [18].
Risk factors 
Several risk factors were associated with post-biopsy in-
fections, including diabetes, a history of prostatitis, pre-
vious biopsies, fluoroquinolone consumption within two 
months prior to biopsy, pre-biopsy bacteriuria and  
faecal carriage of fluoroquinolone resistant E. coli [13, 
16, 18, 21]. One trial demonstrated that faecal carriage 
of ESBL-PE was associated with symptoms of UTI with-
out microbiological evidence [18]. However, no associ-
ation between faecal ESBL carriage and post-procedure 
symptomatic UTI was found. Also, prior use of quino-
lones or other antibiotics, as well as diabetes, were as-
sociated with a risk of carrying ESBL-PE before biopsy  
in multivariate analysis [18]. A second trial found that 
chronic prostatitis and fluoroquinolone consumption 
within six months before biopsy were risk factors associ-
ated with faecal carriage of fluoroquinolone-resistant E. 
coli strains [21]. A further two trials found no correlation 
between infection and either the number of core sam-
ples taken or the procedure being a re-biopsy [16, 21].
Two Danish reports on prophylactic antibiotics and 
post-biopsy infectious complications have been pub-
lished. A retrospective analysis demonstrated a post- 
biopsy sepsis incidence of 0.91% (n = 4) among 438  
patients who underwent TRUS-gb biopsies in the 2009-
2011 period. The antibiotic prophylaxis used was 500 mg 
of CFLX and 500 mg of metronidazole taken before, six 
hours after, and the day after the procedure. E. coli with 
resistance towards CFLX was described as the causative 
pathogen in patients who experienced a post-bioptic 
septic complication [23]. 
The second study considered patients who under-
went TRUS-gb at a single hospital in DK in the 2010-2013 
period, and who were administered three different pro-
phylactic antibiotic regimens, namely CFLX or the com-
bination of pivmecillinam and amoxicillin/clavulanic acid 
for either one or three days [24]. Overall, the admission 
rates due to infectious complications were 1.8%, and the 
most commonly isolated pathogens were E. coli, Kleb-
siella pneumoniae and Enterococcus faecalis. Of these, 
12.1-55.3% were found to harbour resistance towards 
CFLX and 12.1-21.1% towards cephalosporins. Among 
the E. coli isolates, up to 15.8% were ESBL-PE. When 
changing the prophylaxis from CFLX to the pivmecillinam 
and amoxicillin/clavulanic acid combination, a reduction 
in CFLX resistance from 55.3 to 12.1% was seen. 
Prophylactic antibiotic strategies in denmark
We identified 19 departments of urology in DK that per-
form TRUS-gb (table 2). All facilities reported taking out 
10-12 needle cores per biopsy set, and all had a stand-
ard prophylactic regimen prescribed to patients before 
biopsy. The most prevalent regimen was monotherapy 
with CFLX, which was reported by 13 facilities. CFLX in 
combination with metronidazole and amoxicillin + clavu-
lanic acid in combination with mecillinam was reported 
by three and two facilities, respectively. There was much 
variation in the duration of prophylaxis, ranging from a 
single dose to a three-day regimen. 
discUssiOn
Complications following biopsy of the prostate range 
from mild and self-limiting to life-threatening conditions 
requiring prompt medical attention. Antibiotic prophy-
laxis is necessary to reduce the risk of serious infectious 
complications, but the evidence supporting specific regi-
mens remains scarce.
The most commonly reported non-infectious com-
plications following TRUS-gb were haematuria and hae-
mospermia, both with occurrence rates reaching 60%. 
Rectal bleeding was also a frequent complication seen in 
up to 20% of patients. UTI and dysuria were the most 
common infectious complications with occurrence rates 
reaching 9.3% and 13.3%, respectively, whereas sepsis, 
septic shock and death were reported in rates of up to 
5.7%, 0.45% and 0.2%, respectively. The differences in 
the reported incidence of complications may be attri-
buted to different follow-up regimens, different disease 
definitions and different methods of data collection. 
Risk factors associated with septic complications 
have not been rigorously defined, although comorbidity 
and previous use of antibiotics seem to be predisposing 
risk factors. Only quinolones and chloramphenicol have 
been tested in a randomised trial. 
The fact that CFLX is superior to chloramphenicol 
and norfloxacin may not seem surprising when review-
ing drug pharmacokinetics. At least 50-70% of CFLX is  
excreted in the urine as unmetabolised drug, which is 
twice as much as for norfloxacin and chloramphenicol. 
Chloramphenicol is not active against a number of 
Gram-negative strains, some E. coli strains are even 
spontaneously resistant to the drug, and a relatively 
high concentration of chloramphenicol is needed to 
achieve a minimum inhibitory concentration in E. coli 
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bacteria [22]. Interestingly, only one study reported a 
difference in rates of infectious complications between 
quinolone-treated groups [22]. Also, no trials were able 
to demonstrate that administration of several doses of 
antibiotics is superior to a single dose and thus pro-
longed use of antibiotics following TRUS-gb remains con-
troversial [6, 8, 10, 11, 16, 22]. This is in line with the 
findings by Zani et al from 2011 [25]. It remains un-
known whether a single dose compared with several 
doses is associated with an increase in bacterial resist-
ance mechanisms, which could potentially influence the 
risk of infectious complications if patients are scheduled 
for re-biopsy procedures. Consequently, current guide-
lines on antibiotic prophylaxis in association with TRUS-
gb must primarily be based on empirical evidence and 
knowledge about rectal bacterial culture as well as the 
typical response to known antibiotics.
E. coli, Klebsiella spp. and Enterobacter spp. – all 
Gram-negative, facultatively anaerob bacteria – seem to 
be the most commonly isolated bacteria in symptomatic 
patients, and an antibiotic strategy should target these 
species. However, since anaerob culturing of urine or 
blood was not performed systematically, the prevalence 
of strict anaerob bacteria may be underreported. The 
study performing rectal swabs prior to the prostate bi-
opsy demonstrated that almost one fourth of the pa-
tients were carriers of CFLX-resistant bacteria [21]. Thus, 
for patients with increased risk of post-bioptic infections 
(i.e. diabetes, chronic prostatitis and prior use of antibi-
otics), performing a rectal swab that allows for diagnosis 
of resistant bacterial strains may prove valuable in creat-
ing a targeted antibiotic strategy.
Recent studies suggest that an increase in infectious 
complications after prostate biopsies has occurred over 
time [26]. In Canada, an increased risk of hospitalisation 
30 days after TRUS-gb was demonstrated between 1996 
and 2005 (odds ratio = 3.74; 95% confidence interval 
(CI): 2.0-7.0; p < 0.0001) [27]. Similarly, an increase in 
the frequency of hospitalisation due to infectious com-
plications after TRUS-gb of the prostate over a study  
period from 1991 to 2007 (p for trend 0.001) has been 
reported [28]. Repeat biopsies during active surveillance 
have been argued to increase the risk of post-biopsy in-
fectious complications. One trial found the odds of infec-
tious complications after TRUS-gb to increase by 1.33 
with each additional previous biopsy (95% CI: 1.01-1.74; 
p = 0.041) [29]. On the other hand, previous biopsies 
have also been found not to be related to a higher risk 
of post-bioptic complications [21]. 
A range of different measures have been applied to 
the TRUS-gb procedure in an attempt to minimise the 
number and severity of post-bioptic complications, i.e. 
cleansing of the biopsy needle between each biopsy 
[30], pre-bioptic assessment of urine bacterial culture 
[31], the transperineal biopsy technique [32] and the 
use of enemas with or without an added antibiotic. The 
evidence for an improved outcome for these regimens, 
however, remains low. 
the danish perspective 
According to Danish guidelines, population-based PSA 
screening is not recommended and the PSA test is re-
served for symptomatic patients, patients who have 
findings on clinical examination that raise suspicion of 
PCa, or patients with at least two close relatives who 
have suffered from early-onset Pca [33]. Current Danish 
guidelines advocate a set of ten biopsies preceded by 
the administration of prophylactic, but otherwise un-
specified, antibiotics [34]. 
During the past 20 years, DK has witnessed a dram-
atic increase in the incidence of prostate cancer with an 
expected, corresponding increase in the number of 
TRUS-gb performed each year and, accordingly, an in-
creased use of prophylactic antibiotics. According to 
DANMAP, a monitoring programme of the antimicrobial 
resistance in DK, the overall use of antimicrobial agents 
in Danish patients has increased by 20% since 2004, but 
the use of fluoroquinolones has increased by more than 
40%. At the same time, CFLX-resistance in E. coli isolates 
from urine has increased from 3% to 12% among hos-
pitalised patients [35]. Whether this is associated with 
the use of fluoroquinolones when performing TRUS-gb is 
unknown. With CFLX monotherapy being the most com-
monly used prophylaxis for TRUS-gb in DK, the increase 
in CFLX-resistant E. coli raises concern whether a con-
comitant increase in post-biopsy infectious complica-
tions may follow. 
Local clinical guidelines on the use of antibiotics 
with TRUS-gb are not uniform in DK and there seems to 
be considerable variation among the drugs of choice 
even within hospitals of close proximity. CFLX remains 
the most widely used prophylactic antibiotic for TRUS-gb 
in DK, but also metronidazole, amoxicillin/clavulanic acid 
and mecillinam are commonly used. Whether the risk of 
complications varies between institutions is unknown. 
It has been shown that different types of antibiotics 
penetrate differently into the prostate tissue, and the 
mode of administration is also important for the concen-
tration of the antibiotic that is reached in the prostatic 
tissue [36-38]. International guidelines, such as the 
European Association of Urology Guidelines, recom-
mend oral or intravenous administration of a quinolone 
prior to biopsy [39]. The American Urological Association 
recommends oral fluoroquinolones or intravenous or  
intramuscular administration of cephalosporins or tri-
methoprim-sulfamethoxazole as first-choice prophylac-
tic antibiotic [40]. If, however, a rectal swab is per-
formed, the antimicrobial prophylaxis can be adjusted 
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towards the growth result [40], which, according to  
previous studies appears highly efficient in reducing  
infectious complications [41, 42]. Minimising the anti-
micro bial spectrum, the dose and the duration of the 
antibiotic are important when taking into account the 
ecological consequences of antimicrobial use (e.g. the 
development of resistant bacterial strains). Fur ther-
more, with regard to optimal use of antibiotic, the peak 
serum concentration of CFLX is reached 1-3 hours after 
oral intake, which may therefore possibly be considered 
the ideal time for biopsy [6].
cOnclUsiOn
Evidence supporting a specific antibiotic prophylaxis 
strategy for TRUS-gb is scarce. Furthermore, the fre-
quent use of antibiotics in the population in general, the 
surfacing of many resistant bacteria and the fact that 
many men undergo re-biopsies means that is seems dif-
ficult to introduce a uniform, prophylactic antibiotic reg-
imen for TRUS-gb. Patients who develop post-biopsy 
sepsis often harbour bacteria with complex resistance 
patterns; thus, the available microbiological expertise 
should be applied when initiating therapy.
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